Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Other Non-Current Liabilities: 2023

  • Immunome's Other Non-Current Liabilities was N/A to $1.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.3 million, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2023, which is N/A change from last year.
  • As of Q4 2023, Immunome's Other Non-Current Liabilities stood at $1.3 million, which was up 998.36% from $122,000 recorded in Q3 2023.
  • Immunome's Other Non-Current Liabilities' 5-year high stood at $1.3 million during Q4 2023, with a 5-year trough of $122,000 in Q3 2023.
  • Its 1-year average for Other Non-Current Liabilities is $731,000, with a median of $731,000 in 2023.